Youli Zu

Summary

Affiliation: The Methodist Hospital
Country: USA

Publications

  1. pmc A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma
    Nianxi Zhao
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    J Nanobiotechnology 9:2. 2011
  2. doi request reprint Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin MS205, Houston, TX 77030, USA
    Mol Cancer Ther 10:148-58. 2011

Collaborators

  • Nianxi Zhao
  • Jianguo Wen
  • Hitesh G Bagaria
  • Michael Wang
  • Michael S Wong
  • Zheng zheng Shi
  • Yongdong Feng
  • Jacqueline O'Hare
  • Chung Che Chang
  • Bing Liao
  • Robert Z Orlowski
  • Chad C Bjorklund
  • Andrew V Schally

Detail Information

Publications2

  1. pmc A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma
    Nianxi Zhao
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    J Nanobiotechnology 9:2. 2011
    ..However, siRNAs are not cell type-selective, cannot specifically target tumor cells, and therefore have limited in vivo application for siRNA-mediated gene therapy...
  2. doi request reprint Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin MS205, Houston, TX 77030, USA
    Mol Cancer Ther 10:148-58. 2011
    ..Our findings indicate that Cetrorelix induces cytotoxicity in myeloma cells through various mechanisms and provide a rationale for investigating Cetrorelix for the treatment of MM...

Research Grants3

  1. Role of MAP kinases in anaplastic large cell lymphoma
    Youli Zu; Fiscal Year: 2007
    ..More importantly, the resultant findings may lead to therapeutic advances for ALCL by identifying key signaling molecules in the lymphoma cells. ..
  2. A bifunctional nanomedicine for both specific imaging and targeting therapy of an
    Youli Zu; Fiscal Year: 2010
    ..In addition, it should enable physicians to in vivo image ALCL tumors and monitor therapeutic responses in a real-time manner. ..